ClinicalTrials.gg
Active, not recruitingNCT03770832Updated Jan 21, 2026

Wearable Sensors and Video Recordings to Monitor Motor Development

An observational study in Motor Delay, Neurodevelopmental Disorders and Developmental Disability, sponsored by Shirley Ryan AbilityLab. Active, not recruiting at 2 sites in United States. Open to participants aged 0 Months to 24 Months. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by Shirley Ryan AbilityLab · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
0 Months to 24 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Psychomotor Disorders with a site in United States — 5 open to participants now, 7 under way, none of them phase 3. Psychomotor Disorders · United States.

Started
2019
with 1 other
Observational
5 of 15
3 open now
Registered
6th of 15
by date
Lead sponsor
3 of 15
Shirley Ryan AbilityLab

Among the 15 studies in Psychomotor Disorders with a site in United States, this one is one of 2 that started in 2019, is one of 5 observational ones, and was the 6th registered.

Psychomotor Disorders

51 studies on the registry are indexed under Psychomotor Disorders; 8 are open to participants now.

Browse Psychomotor Disorders studies →

Open to participants now

5 of the 15 studies in Psychomotor Disorders with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Psychomotor Disorders studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 0 Months to 24 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Psychomotor Disorders with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to develop an automated, precise, quantitative assay for detecting atypical motor behavior and development in infants using data from wearable sensors and video recordings.

03

Conditions studied

  • Motor Delay
  • Neurodevelopmental Disorders
  • Developmental Disability

Keywords

  • Early Detection
  • Wearable Sensors
  • Computer Vision
04

Who can participate

Ages eligible
0 Months to 24 Months
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals at high risk of developing motor delays \<24 months of age along with infants at low risk of developing motor delays.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals identified as potentially at risk of abnormal motor development due to a risk factor (for example, prematurity, neonatal hypoxic ischemic encephalopathy, or neonatal stroke) OR control individuals for whom normal motor development is expected.
  • Age: \< 24 months of age
  • Legal guardian able and willing to give written consent and comply with study procedures.
  • In case of multiple pregnancies, only one child selected at random will participate in the research activities. Study staff will have no influence over the selection, besides any known medical condition automatically excluding the baby as listed in our exclusion criteria.

Exclusion criteria

Exclusion Criteria:

  • Any open wound or skin breakdown on the limbs or upper torso.
  • Missing or incomplete limbs (such as from amputation or congenital limb defects)
  • Legal guardian unable to give written consent and comply with study procedures.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Infants at Risk for Atypical Motor Development (high-risk)
  • Infants Expected to Have Typical Motor Development (low-risk)
06

What researchers measure

Primary outcomes

  1. Three month clinical score estimation

    Error between true clinical test scores and scores estimated from sensor and video data, assessed at the 3 month time-point.

    Time frame: 3 months

  2. Six month clinical score estimation

    Error between true clinical test scores and scores estimated from sensor and video data, assessed at 6 month time-point.

    Time frame: 6 months

  3. Prediction of neuromotor outcome using sensor and video data from 3 month time-point

    Sensitivity and specificity of algorithm (trained on sensor and video data from the 3 month time-point) to predict neuromotor outcome at final study visit (as measured by the Peabody Developmental Motor Scales, second edition \[PDMS-2\])

    Time frame: 3 months

  4. Prediction of neuromotor outcome using sensor and video data from 6 month time-point

    Sensitivity and specificity of algorithm (trained on sensor and video data from the 6 month time-point) to predict neuromotor outcome at final study visit (as measured by the Peabody Developmental Motor Scales, second edition \[PDMS-2\])

    Time frame: 6 months

Secondary outcomes

  1. Prediction of neuromotor outcome using General Movements Assessment (GMA) scores

    Sensitivity and specificity of GMA scores (taken at 1-2 weeks, 1 month, 3 months) to predict neuromotor outcome at final study visit (as measured by the Peabody Developmental Motor Scales, second edition \[PDMS-2\]). The GMA is an observational exam where an infant's spontaneous movements are scored as atypical or normal for their age.

    Time frame: 1-2 weeks, 1 month, 3 months

  2. Prediction of neuromotor outcome using Alberta Infant Motor Scale (AIMS) scores

    Sensitivity and specificity of AIMS scores (taken at 6 months, 9 months, 1 year) to predict neuromotor outcome at final study visit (as measured by the Peabody Developmental Motor Scales, second edition \[PDMS-2\]). The AIMS is a norm-referenced observational assessment with a minimum score of 0 and a maximum score of 58. Higher scores indicate better motor performance on the assessment.

    Time frame: 6 months, 9 months, 1 year

  3. Prediction of neuromotor outcome using Hammersmith Infant Neurological Examination (HINE) scores

    Sensitivity and specificity of HINE scores (taken at 6 months, 9 months, 1 year) to predict neuromotor outcome at final study visit (as measured by the Peabody Developmental Motor Scales, second edition \[PDMS-2\]). The HINE is a neurological exam with a minimum score of 0 and a maximum score of 78. Higher scores indicate better performance on the assessment.

    Time frame: 6 months, 9 months, 1 year

  4. Prediction of neuromotor outcome using Test of Infant Motor Performance (TIMP) scores

    Sensitivity and specificity of TIMP scores (taken at 1-2 weeks, 1 month, 3 months) to predict neuromotor outcome at final study visit (as measured by the Peabody Developmental Motor Scales, second edition \[PDMS-2\]).

    Time frame: 1-2 weeks, 1 month, 3 months

  5. Clinical score estimation

    Error between true clinical test scores and scores estimated from sensor and video data, assessed at each remaining time-point.

    Time frame: 1-2 weeks, 1 month, 9 months, 1 year, 2 years

  6. Prediction of neuromotor outcome at 2 years using sensor and video data from the remaining time-points

    Sensitivity and specificity of algorithm (trained on sensor and video data from the remaining time-points) to predict neuromotor outcome at 2 years (as measured by the Peabody Developmental Motor Scales, second edition \[PDMS-2\])

    Time frame: 1-2 weeks, 1 month, 9 months, 1 year, 2 years

Other outcomes

  1. Prediction of neuromotor outcome using NICU Network Neurobehavioral Scale (NNNS) scores

    Sensitivity and specificity of NNNS scores (taken at 1 month) to predict neuromotor outcome at final study visit (as measured by the Peabody Developmental Motor Scales, second edition \[PDMS-2\])

    Time frame: 1 month

07

Study locations

2 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2019 (actual). Primary completion is estimated for Dec 2026, 93 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2018
First posted
Dec 10, 2018
StartActual
Mar 29, 2019
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03770832
Responsible party
Arun Jayaraman, PT, PhD (Principal Investigator, Shirley Ryan AbilityLab) — Principal investigator
First posted
Dec 10, 2018
Start date
Mar 29, 2019
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 21, 2026

Study contacts

Arun Jayaraman, PT, PhD
principal investigator · Shirley Ryan AbilityLab

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion